Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

95 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Designing, implementing and evaluating the overdose response with take-home naloxone model of care: An evaluation of client outcomes and perspectives.
Lintzeris N, Monds LA, Bravo M, Read P, Harrod ME, Gilliver R, Wood W, Nielsen S, Dietze PM, Lenton S, Shanahan M, Jauncey M, Jefferies M, Hazelwood S, Dunlop AJ, Greenaway M, Haber P, Ezard N, Malcom A. Lintzeris N, et al. Among authors: hazelwood s. Drug Alcohol Rev. 2020 Jan;39(1):55-65. doi: 10.1111/dar.13015. Epub 2019 Nov 27. Drug Alcohol Rev. 2020. PMID: 31774221
Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study.
Bajis S, Grebely J, Hajarizadeh B, Applegate T, Marshall AD, Ellen Harrod M, Byrne J, Bath N, Read P, Edwards M, Gorton C, Hayllar J, Cock V, Peterson S, Thomson C, Weltman M, Jefferies M, Wood W, Haber P, Ezard N, Martinello M, Maher L, Dore GJ; LiveRLife Study Group. Bajis S, et al. J Viral Hepat. 2020 Mar;27(3):281-293. doi: 10.1111/jvh.13233. Epub 2019 Dec 6. J Viral Hepat. 2020. PMID: 31698545
Assessment and delivery of treatment for hepatitis C virus infection in an opioid substitution treatment clinic with integrated peer-based support in Newcastle, Australia.
Keats J, Micallef M, Grebely J, Hazelwood S, Everingham H, Shrestha N, Jones T, Bath N, Treloar C, Dore GJ, Dunlop A; ETHOS Study Group. Keats J, et al. Among authors: hazelwood s. Int J Drug Policy. 2015 Oct;26(10):999-1006. doi: 10.1016/j.drugpo.2015.07.006. Epub 2015 Jul 17. Int J Drug Policy. 2015. PMID: 26275578
Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist Therapy.
Cunningham EB, Hajarizadeh B, Amin J, Litwin AH, Gane E, Cooper C, Lacombe K, Hellard M, Read P, Powis J, Dalgard O, Bruneau J, Matthews GV, Feld JJ, Dillon JF, Shaw D, Bruggmann P, Conway B, Fraser C, Marks P, Dore GJ, Grebely J; SIMPLIFY and D3FEAT study groups. Cunningham EB, et al. Clin Infect Dis. 2020 Oct 23;71(7):e115-e124. doi: 10.1093/cid/ciz1089. Clin Infect Dis. 2020. PMID: 31677262 Free article.
Evaluation of two community-controlled peer support services for assessment and treatment of hepatitis C virus infection in opioid substitution treatment clinics: The ETHOS study, Australia.
Treloar C, Rance J, Bath N, Everingham H, Micallef M, Day C, Hazelwood S, Grebely J, Dore GJ. Treloar C, et al. Among authors: hazelwood s. Int J Drug Policy. 2015 Oct;26(10):992-8. doi: 10.1016/j.drugpo.2015.01.005. Epub 2015 Jan 24. Int J Drug Policy. 2015. PMID: 25697089
Health-Related Quality of Life of People Who Inject Drugs: The Enhancing Treatment of Hepatitis C in Opioid Substitution Settings Engage Study.
Cheng Q, Valerio H, Cunningham EB, Shih STF, Silk D, Conway A, Treloar C, Murray C, Henderson C, Amin J, Read P, Dore GJ, Grebely J; ETHOS Engage Study Group. Cheng Q, et al. Value Health. 2024 Feb;27(2):216-225. doi: 10.1016/j.jval.2023.10.013. Epub 2023 Nov 10. Value Health. 2024. PMID: 37951538 Free article.
95 results